Company news

INmune Bio Inc. news in 2022

INmune Bio Inc.'s news releases, calls and decks from 2022, newest first.

View company

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

December 5, 2022

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

November 13, 2022

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

November 1, 2022

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

October 25, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

October 18, 2022

INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

August 2, 2022

INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

July 26, 2022

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases

June 21, 2022

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

June 15, 2022

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

May 22, 2022

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

May 9, 2022

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

May 4, 2022

INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

April 27, 2022

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease

April 12, 2022

INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit

March 29, 2022

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases

March 14, 2022

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update

March 2, 2022

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3

February 22, 2022

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

January 24, 2022

Calls in 2022

Decks in 2022